Genmab

	24/10 14:31 af kkjoel	In Japan, some Genmab-originated medicines are already available through partners, but not via its Japan outpost. Farthest along in development towards its first stand-alone product approval are two drug candidates. One is tisotumab vedotin, an antibody-drug conjugate (ADC) for cervical cancer, which is approved in the US under the brand name of Tivdak. The other is the bispecific antibody epcoritamab for the treatment of non-Hodgkin’s lymphoma...
	24/10 14:31 af kkjoel	[Nyt afsnit] 50-Plus Employees in Japan...
	24/10 14:30 af kkjoel	to prune costs...
	24/10 14:30 af kkjoel	In the meantime, Dr van de Winkel also spoke about ways to address the challenge of rising drug prices seen in tandem with the diversification of modalities, stressing the need to curb R&D and manufacturing costs to ensure access to medicines. “I think we need to develop medicines more effectively and in shorter periods of time in the future,” said the CEO, explaining that Genmab is looking into an approach to work with data science companies to shorten the development process thereby...
	24/10 14:30 af kkjoel	“The Japanese system is complex and it’s dynamic, but I would argue that also the US system is very complex and dynamic. I mean, there was recent legislation, which is potentially completely changing the reimbursement of medicines in the US,” he said. “Europe is even more difficult to navigate,” he continued, explaining that it takes years for some countries to set prices for new medicines. “I would say that Japan is not necessarily more complex than other systems,” he added...
	24/10 14:29 af kkjoel	Japan has an advanced healthcare system that reimburses for innovative medicines, he said, while also expressing hopes for collaborations with academic and other research institutes...
	24/10 14:29 af kkjoel	On Japan, Dr van de Winkel said that it is a “priority market” alongside the US, with these two being the only countries where Genmab is building out its independent commercial infrastructure. Cancer medicines often fall victim to big price slashes under market expansion re-pricing rules in Japan, but he said that the market is “still very attractive” for innovative companies...
	24/10 14:29 af kkjoel	[Nyt afsnit] Japan Still Attractive...
	24/10 14:28 af kkjoel	Introducing these two examples, Dr van de Winkel highlighted the potential of the company’s drug discovery technologies for the development of products in other therapeutic areas. With increasing profitability, Genmab is now prepping an R&D foray into one additional disease space. “We have not yet finally decided where to go,” said the CEO, noting that the company is testing out multiple candidates preclinically to see which ones could be brought into the clinic for further development...
	24/10 14:28 af kkjoel	Already now, two of the six Genmab technology-based products are on the market outside of cancer. Kesimpta and Tepezza were initially developed by the biotech as cancer therapies, but their licensing partners repurposed them for multiple sclerosis and thyroid eye disease, respectively, during the development process...
	24/10 14:28 af kkjoel	“We have a growing, what we call, recurring income stream (from royalties), which is getting bigger and bigger and bigger. So, we actually are quite well off from a capital perspective. We can actually then use that capital to invest in creating new products and holding onto more product rights,” said Dr van de Winkel in a Tokyo interview on October 21...
	24/10 14:27 af kkjoel	Its current pipeline boasts 20 assets. In recent years, the company has been pivoting away from its original pure out-licensing scheme towards a business model based on codevelopment and stand-alone commercialization, which started to financially pay off from last year. Cancer medicines will remain the growth driver of the company in the coming years...
	24/10 14:27 af kkjoel	Since its inception 23 years ago, the Copenhagen-headquartered biotech has originated 40 pipeline candidates, of which six have been approved to date via partner firms. Among them are major products such as Novartis’ Kesimpta (ofatumumab) and Arzerra (ofatumumab), Janssen’s Darzalex (daratumumab) and Horizon Therapeutics’ Tepezza (teprotumumab)...
	24/10 14:27 af kkjoel	Genmab, a Danish antibody developer focused on oncology, is set to expand its R&D into a new therapeutic area, with the specific target field to be announced next year. The company will harness its bispecific and hexamer formation platforms and steady revenue stream to now generate drugs for non-cancer diseases, CEO Jan van de Winkel told Jiho...
	24/10 14:26 af kkjoel	(link) "Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO....
	24/10 14:26 af kkjoel	Han gav et interview i Tokyo 21.10, fremgår det af artiklen. Paster den her... de kan bare sagsøge, ka' de......
	24/10 14:07 af Sukkeralf	Probably not more than they will disclose the disease area next year - it could be a small thing or it could be bigger
	24/10 13:58 af Bulder	If there is anything new in the article, it will surely pop up in Medwatch soon.
	24/10 13:55 af Bulder	... we will remain open to other potential indications outside of cancer with the ultimate goal of improving the lives of as many people as possible through our innovative and differentiated antibody therapeutics.
	24/10 13:55 af Bulder	Could also just be based on what Winkel said at Q2 CC: We know that our antibody know-how assets and technologies can be applied to diseases outside of cancer. The approval of Novartis's Kesimpta in ofatumumab and a rise in Tepezza to in thyroid eye disease are proof of this. So while we will continue to create and develop new treatment concepts in oncology, ...
	24/10 13:43 af Sukkeralf	Could be E L - but somewhat strange that its the headline of the article.
	24/10 12:57 af ProInvestorNEWS	Investeringsstrateg har godt øje til defensive aktier (link)
	24/10 12:38 af E L	@12.04 dunno... maybe Jan is in Japan or a local manager gave an interview, they have an office there...
	24/10 12:05 af Sukkeralf	If Janssen dont take the HexaCD38 option RA would be the obvious

	24/10 12:04 af Sukkeralf	But why is this mentioned in Pharma Japan
	24/10 12:03 af Sukkeralf	Guess it will be impossible to figure out the partner now - so many could be interesting.
	24/10 11:54 af Bulder	If autoimmune, then why not Roche? But there are many players in that field.
	24/10 11:09 af E L	could very well be, will be interesting if any of Genmab's partnerships will contribute, we don't hear much from those
	24/10 10:26 af Bulder	From Q2: Our 2030 Vision: By 2030, our KYSO antibody medicines are fundamentally transforming the lives of people with cancer and other serious diseases. - My guess would be infections or autoimmune.
	24/10 10:15 af E L	anybody subscribing to 'PHARMA JAPAN'...? ;-) - Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO (link)
	24/10 08:32 af Doublo	God morgen :-)USA sluttede 36,92 = 2789 dkr. håber det smitter af i Danmark.
	24/10 06:23 af ProInvestorNEWS	Godmorgen :-)
	24/10 06:16 af Stroka	God morgen :-)
	24/10 06:07 af Helge Larsen/PI-redaktør	Godmorgen. :-)
	23/10 12:37 af ProInvestorNEWS	Selskaber shortet på det danske aktiemarked pr. 21/10-2022 (link)
	22/10 16:35 af E L	New Real-World Analysis of TEPEZZA® (teprotumumab-trbw) Use Indicates a Small Percentage of People Receive a Second Course of Treatment (link)
	22/10 10:58 af StockBull	Derfor jeg foretrækker, at handle aktier :-)
	22/10 10:54 af StockBull	Ja korrekt der er 16 røde, 16 sorte og 1 grøn som jeg lige husker. 16/33 så 48.485% sandsynlig for profit i hvert spil
	22/10 04:33 af StockBull	Kan også være dem som har solgt i 2750-2850 niveau i DK som køber tilbage i USA i 2650-2800 niveau.
	21/10 20:48 af Solsen	Ahh lidt mindre. Dolleren er nede i dag.
	21/10 20:35 af Solsen	Handler i +2800 DKK i US
	21/10 16:52 af E L	it was apparently one of the he largest monthly option expiries on record (SPX)- so some volatility was to be expected. Even though Genmab has hardly any option trading, there is still exposure through the various indices and ETF's
	21/10 16:21 af AaBforever	Ja der er "svuung" over aktier i dag.
	21/10 15:57 af StockBull	Smukt, nærmest kunst at se 2651 og så tilbage til 2720. Som tidligere nævnt, træet skulle lige rystes.
	21/10 14:31 af Helge Larsen/PI-redaktør	Kort video - Videoen er den anden fra mig i en serie af løbende indslag omkring det, at være investor i et bear-marked. I denne video giver jeg indblik i, hvilke aktier, jeg selv synes er interessante i øjeblikket. (link)
	21/10 14:22 af JKY_VH	:-D
	21/10 14:04 af nohope	Jeg synes, det lugter af en kommisionsundersøgelse er påkrævet.
	21/10 13:23 af Riis7	hvad var aftalen:-)?
	21/10 13:10 af nohope	Det er Jylland, og hvis det her fortsætter så bliver det danskvand med citronsmag.
	21/10 13:04 af nohope	Havde egentlig planlagt at købe cremant i dag, men det kan vist godt udsættes....